Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models

BACKGROUND: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination with gemcitabine (ATRi/gem), we investigated ATM l...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlop, Charles R., Wallez, Yann, Johnson, Timothy Isaac, Bernaldo de Quirós Fernández, Sandra, Durant, Stephen T., Cadogan, Elaine B., Lau, Alan, Richards, Frances M., Jodrell, Duncan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591912/
https://www.ncbi.nlm.nih.gov/pubmed/32741974
http://dx.doi.org/10.1038/s41416-020-1016-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591912/
https://www.ncbi.nlm.nih.gov/pubmed/32741974
http://dx.doi.org/10.1038/s41416-020-1016-2

Ejemplares similares